Fyn kinase is involved in cleavage furrow ingression during meiosis and mitosis.
Fertilization of mammalian oocytes triggers their exit from the second meiotic division metaphase arrest. The extrusion of the second polar body (PBII) that marks the completion of meiosis is followed by the first mitotic cleavage of the zygote. Several lines of evidence in somatic cells imply the involvement of Fyn, an Src family kinase (SFK), in cell cycle control and actin functions. In this study, we demonstrate, using live cell confocal imaging and microinjection of Fyn cRNAs, the recruitment of Fyn to the oocyte's cortical area overlying the chromosomes and its colocalization with filamentous actin (F-actin) during exit from the meiotic metaphase. Fyn concentrated asymmetrically at the cortical site designated for ingression of the PBII cleavage furrow, where F-actin had already been accumulated, and then redispersed throughout the entire cortex only to be recruited again to the cleavage furrow during the first mitotic division. Although microinjection of dominant negative Fyn did not affect initiation of the cleavage furrow, it prolonged the average duration of ingression, decreased the rates of PB extrusion and of the first cleavage, and led to the formation of bigger PBs and longer spindles. Extrusion of the PBII was blocked in oocytes exposed to SU6656, an SFK inhibitor. Our results demonstrate, for the first time, a continuous colocalization of Fyn and F-actin during meiosis and imply a role for the SFKs, in general, and for Fyn, in particular, in regulating pathways that involve actin cytoskeleton, during ingression of the meiotic and mitotic cleavage furrows.
Levi
Mattan
M
Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Tel-Aviv 69978, Israel.
Maro
Bernard
B
Shalgi
Ruth
R
D000199:Actins / Q000378:metabolism; D000818:Animals; D002970:Cleavage Stage, Ovum / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D005260:Female; D005306:Fertilization / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D007211:Indoles / Q000494:pharmacology; D008540:Meiosis / Q000187:drug effects / Q000235:genetics*; D051379:Mice; D008813:Mice, Inbred ICR; D008845:Microinjections; D008938:Mitosis / Q000187:drug effects / Q000235:genetics*; D009866:Oogenesis / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D051076:Proto-Oncogene Proteins c-fyn / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D008941:Spindle Apparatus / Q000187:drug effects / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D013449:Sulfonamides / Q000494:pharmacology; D014162:Transfection; D019061:src-Family Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism / Q000502:physiology
D000199:Actins; D007211:Indoles; D047428:Protein Kinase Inhibitors; C416927:SU 6656; D013449:Sulfonamides; C494960:Fyn protein, mouse; D051076:Proto-Oncogene Proteins c-fyn; D019061:src-Family Kinases